Mercoledì 20 marzo 2024 ore 16.00, presso l’Auditorium Prima Clinica Medica (Edificio 6) del Policlinico Umberto I, si terrà una conferenza dell’Accademia Medica Romana nella quale Antonio Bertoletti, MD Professor, Emerging Infectious Diseases, Duke-Nus Medical School, parlerà sul tema: “T cell engineering in HCC/HBV therapy”.

mRNA-based T cell engineering for treatment of virus-related cancer and virus infection.

Adoptive therapy with T cells engineered with a Chimeric Antigen Receptor (CAR) or a classical T Cell Receptor (TCR) -indicated as CAR/TCR-T cells- transitioned from an experimental approach to a main strategy of care in cancer treatment. However, while clinical success has been remarkable in some hematological cancers (i.e., B cell lymphoma), efficacy has been limited in solid tumors, and the production cost can limit its usage in clinical practice. We have already utilized the flexibility of mRNA electroporation technology in engineering mRNA TCR-T cells for the production of HBV- and SARS-CoV-2-specific T cells. mRNA-HBV-specific TCR-T cells have also been used in clinical trials for the treatment of primary and secondary HBV-related hepatocellular carcinoma (HCC). I will discuss the advantages (no genetic modifications, escalating doses to limit side effects, cost) and limitations (transient functionality, multiple infusions) of this approach. I will also present novel data that suggest that adoptive transfer of mRNA HBV-TCR-T cells in patients with HBV-related HCC can modify liver tumor environment and allow induction of novel T cell specificities with ability to target the tumor and HBV.

La conferenza potrà essere seguita in presenza presso la sede sopra descritta oppure in streaming sulla
piattaforma Zoom utilizzando il seguente link
https://uniroma1.zoom.us/j/92312414393?pwd=cDM2bTZ3VldoWEFjSnNJNXR6bmtJdz09
(Meeting ID: 923 1241 4393; Passcode: accademia)

Il certificato di partecipazione verrà rilasciato solo in presenza